Tamoxifen and carboplatin for children with low-grade gliomas: A pilot study at st. jude children’s research hospital

Andrew W. Walter, Amar Gajjar, David A. Reardon, Stephen J. Thompson, James W. Langston, Dana Jones-Wallace, Larry E. Kun, Richard L. Heideman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: The authors conducted a single-arm, prospective study using tamoxifen and carboplatin for the treatment of children with progressive or symptomatic low-grade gliomas. Patients and Methods: Fourteen children with consecutively diagnosed cases of low-grade glioma were enrolled in this study; all patients were younger than 14 years. One patient was excluded after induction chemotherapy because of the diagnosis of a nonmalignant condition. Patients were treated with daily tamoxifen (20 mg/m2 administered twice per day) in addition to targeted, monthly intravenous carboplatin at an area under the curve (AUC) exposure of 6.5 mg/mL × minute for 1 year or until they had clinical or radiologic evidence of disease progression. Results: The median age at diagnosis was 5.3 years, the median age at initiation of chemotherapy was 8.3 years. Eight patients had tumors of the hypothalamus/optic pathway, two patients had thalamic tumors, and one patient each had tumors in the temporal lobe, tectum, and brain stem. Tumor histologic findings included fibrillary astrocytoma (n = 2), juvenile pilocytic astrocytoma (n = 6), and oligodendroglioma (n = 1). The best response to therapy was a partial response in two patients, stable disease in nine patients, and progressive disease in two patients. The overall survival at 3 years is 69%. The 3-year progression-free survival is 47%. Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas. The progression-free survival is similar to that of other published series. Nonmyelosuppressive agents such as tamoxifen deserve additional evaluation in the treatment of children with low-grade gliomas.

Original languageEnglish (US)
Pages (from-to)247-251
Number of pages5
JournalAmerican Journal of Pediatric Hematology/Oncology
Volume22
Issue number3
StatePublished - Jan 1 2000

Fingerprint

Carboplatin
Tamoxifen
Glioma
Research
Astrocytoma
Disease-Free Survival
Hypothalamic Neoplasms
Oligodendroglioma
Drug Therapy
Neoplasms
Induction Chemotherapy
Temporal Lobe
Brain Stem
Area Under Curve
Disease Progression
Therapeutics
Prospective Studies
Survival

Keywords

  • Brain tumors
  • Carboplatin
  • Chemotherapy
  • Children
  • Low-grade glioma
  • Tamoxifen

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Walter, A. W., Gajjar, A., Reardon, D. A., Thompson, S. J., Langston, J. W., Jones-Wallace, D., ... Heideman, R. L. (2000). Tamoxifen and carboplatin for children with low-grade gliomas: A pilot study at st. jude children’s research hospital. American Journal of Pediatric Hematology/Oncology, 22(3), 247-251.

Tamoxifen and carboplatin for children with low-grade gliomas : A pilot study at st. jude children’s research hospital. / Walter, Andrew W.; Gajjar, Amar; Reardon, David A.; Thompson, Stephen J.; Langston, James W.; Jones-Wallace, Dana; Kun, Larry E.; Heideman, Richard L.

In: American Journal of Pediatric Hematology/Oncology, Vol. 22, No. 3, 01.01.2000, p. 247-251.

Research output: Contribution to journalArticle

Walter, AW, Gajjar, A, Reardon, DA, Thompson, SJ, Langston, JW, Jones-Wallace, D, Kun, LE & Heideman, RL 2000, 'Tamoxifen and carboplatin for children with low-grade gliomas: A pilot study at st. jude children’s research hospital', American Journal of Pediatric Hematology/Oncology, vol. 22, no. 3, pp. 247-251.
Walter, Andrew W. ; Gajjar, Amar ; Reardon, David A. ; Thompson, Stephen J. ; Langston, James W. ; Jones-Wallace, Dana ; Kun, Larry E. ; Heideman, Richard L. / Tamoxifen and carboplatin for children with low-grade gliomas : A pilot study at st. jude children’s research hospital. In: American Journal of Pediatric Hematology/Oncology. 2000 ; Vol. 22, No. 3. pp. 247-251.
@article{f5f8f691eac84206b135578dcc64180c,
title = "Tamoxifen and carboplatin for children with low-grade gliomas: A pilot study at st. jude children’s research hospital",
abstract = "Purpose: The authors conducted a single-arm, prospective study using tamoxifen and carboplatin for the treatment of children with progressive or symptomatic low-grade gliomas. Patients and Methods: Fourteen children with consecutively diagnosed cases of low-grade glioma were enrolled in this study; all patients were younger than 14 years. One patient was excluded after induction chemotherapy because of the diagnosis of a nonmalignant condition. Patients were treated with daily tamoxifen (20 mg/m2 administered twice per day) in addition to targeted, monthly intravenous carboplatin at an area under the curve (AUC) exposure of 6.5 mg/mL × minute for 1 year or until they had clinical or radiologic evidence of disease progression. Results: The median age at diagnosis was 5.3 years, the median age at initiation of chemotherapy was 8.3 years. Eight patients had tumors of the hypothalamus/optic pathway, two patients had thalamic tumors, and one patient each had tumors in the temporal lobe, tectum, and brain stem. Tumor histologic findings included fibrillary astrocytoma (n = 2), juvenile pilocytic astrocytoma (n = 6), and oligodendroglioma (n = 1). The best response to therapy was a partial response in two patients, stable disease in nine patients, and progressive disease in two patients. The overall survival at 3 years is 69{\%}. The 3-year progression-free survival is 47{\%}. Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas. The progression-free survival is similar to that of other published series. Nonmyelosuppressive agents such as tamoxifen deserve additional evaluation in the treatment of children with low-grade gliomas.",
keywords = "Brain tumors, Carboplatin, Chemotherapy, Children, Low-grade glioma, Tamoxifen",
author = "Walter, {Andrew W.} and Amar Gajjar and Reardon, {David A.} and Thompson, {Stephen J.} and Langston, {James W.} and Dana Jones-Wallace and Kun, {Larry E.} and Heideman, {Richard L.}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "22",
pages = "247--251",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Tamoxifen and carboplatin for children with low-grade gliomas

T2 - A pilot study at st. jude children’s research hospital

AU - Walter, Andrew W.

AU - Gajjar, Amar

AU - Reardon, David A.

AU - Thompson, Stephen J.

AU - Langston, James W.

AU - Jones-Wallace, Dana

AU - Kun, Larry E.

AU - Heideman, Richard L.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Purpose: The authors conducted a single-arm, prospective study using tamoxifen and carboplatin for the treatment of children with progressive or symptomatic low-grade gliomas. Patients and Methods: Fourteen children with consecutively diagnosed cases of low-grade glioma were enrolled in this study; all patients were younger than 14 years. One patient was excluded after induction chemotherapy because of the diagnosis of a nonmalignant condition. Patients were treated with daily tamoxifen (20 mg/m2 administered twice per day) in addition to targeted, monthly intravenous carboplatin at an area under the curve (AUC) exposure of 6.5 mg/mL × minute for 1 year or until they had clinical or radiologic evidence of disease progression. Results: The median age at diagnosis was 5.3 years, the median age at initiation of chemotherapy was 8.3 years. Eight patients had tumors of the hypothalamus/optic pathway, two patients had thalamic tumors, and one patient each had tumors in the temporal lobe, tectum, and brain stem. Tumor histologic findings included fibrillary astrocytoma (n = 2), juvenile pilocytic astrocytoma (n = 6), and oligodendroglioma (n = 1). The best response to therapy was a partial response in two patients, stable disease in nine patients, and progressive disease in two patients. The overall survival at 3 years is 69%. The 3-year progression-free survival is 47%. Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas. The progression-free survival is similar to that of other published series. Nonmyelosuppressive agents such as tamoxifen deserve additional evaluation in the treatment of children with low-grade gliomas.

AB - Purpose: The authors conducted a single-arm, prospective study using tamoxifen and carboplatin for the treatment of children with progressive or symptomatic low-grade gliomas. Patients and Methods: Fourteen children with consecutively diagnosed cases of low-grade glioma were enrolled in this study; all patients were younger than 14 years. One patient was excluded after induction chemotherapy because of the diagnosis of a nonmalignant condition. Patients were treated with daily tamoxifen (20 mg/m2 administered twice per day) in addition to targeted, monthly intravenous carboplatin at an area under the curve (AUC) exposure of 6.5 mg/mL × minute for 1 year or until they had clinical or radiologic evidence of disease progression. Results: The median age at diagnosis was 5.3 years, the median age at initiation of chemotherapy was 8.3 years. Eight patients had tumors of the hypothalamus/optic pathway, two patients had thalamic tumors, and one patient each had tumors in the temporal lobe, tectum, and brain stem. Tumor histologic findings included fibrillary astrocytoma (n = 2), juvenile pilocytic astrocytoma (n = 6), and oligodendroglioma (n = 1). The best response to therapy was a partial response in two patients, stable disease in nine patients, and progressive disease in two patients. The overall survival at 3 years is 69%. The 3-year progression-free survival is 47%. Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas. The progression-free survival is similar to that of other published series. Nonmyelosuppressive agents such as tamoxifen deserve additional evaluation in the treatment of children with low-grade gliomas.

KW - Brain tumors

KW - Carboplatin

KW - Chemotherapy

KW - Children

KW - Low-grade glioma

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0034455249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034455249&partnerID=8YFLogxK

M3 - Article

C2 - 10864056

AN - SCOPUS:0034455249

VL - 22

SP - 247

EP - 251

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -